A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Occurring Dates
to
Participant Duration
21 visits over 5 years
State of study
Victoria
Overview

We are doing this study to see if the new medicine called semaglutide can help people with early Alzheimer’s disease. This will be done by comparing semaglutide against placebo on the effect on cognition and daily functioning.

This study has been approved the the St Vincent's NSW Human Research Ethics Committee (approval number 2021/ETH00728)

Participation details

We are seeking participants who meet the following criteria:

  • Age 55-85 years
  • Diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease
  • A study partner who will accompany you to all study visits
  • Lives in Victoria and can attend the Austin Repatriation hospital

Participation in this study includes

  • Memory tests and questionnaires on how well you manage daily routines
  • A brain MRI or CT scan to look at brain structure
  • Blood samples
  • A PET brain scan or a spinal tap to test for amyloid (a protein involved in Alzheimer’s disease)

If you are interested in participating or would like further information, please contact Laura Margison (details below)

Study Address
Medical and Cognitive Research Unit
Austin Repatriation hospital
300 Waterdale road
Ivanhoe, VIC, 3079
Full Name
Laura Margison
Institute
Austin Health
Email
[email protected]
Phone Number
03 9496 4238